How do you select systemic therapy for recurrent HR+ HER2 negative breast cancer in the bones in a premenopausal woman within a year of starting adjuvant AI with OFS plus abemaciclib and zoledronic acid?

She had been initially treated with neoadjuvant AC-T followed by BCS and RT with high burden residual disease in the breast and lymph nodes.

Answer from: Medical Oncologist at Community Practice

This is, unfortunately, a case of primary endocrine resistance, and recurrence on adjuvant Abemaciclib makes the case more challenging for this pre-menopausal patient.It would be reasonable to repeat tissue biopsy to rule out a change in hormone receptor status and consider blood based ctDNA analysi...

Comments

Medical Oncologist at Locum Tenens
Insightful! Thank you.

Medical Oncologist at NYU Winthrop Hospital
You put all choices, nothing is left.

Please select the option that best describes you:

How do you select systemic therapy for recurrent HR+ HER2 negative breast cancer in the bones in a premenopausal woman within a year of starting adjuvant AI with OFS plus abemaciclib and zoledronic acid?

Related Questions